Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Clarifying the Optimal Application of SLT Therapy Trial
NCT04967989 · View on ClinicalTrials.gov ↗
Study Summary
The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.
Conditions Studied
Interventions
- PROCEDURE Low Energy SLT
- PROCEDURE Standard Energy SLT
Study Locations (20)
California
- Harvard Eye Associates — Laguna Hills
- Doheny Eye Center UCLA — Pasadena
- University of California, Davis — Sacramento
- University of California, San Francisco — San Francisco
Illinois
- Northwestern Medical Group — Chicago
- Chicago Arbor Eye Institute — Orland Park
- Illinois Eye Center — Peoria
Massachusetts
- Massachusetts Eye and Ear — Boston
- Ophthalmic Consultants of Boston — Boston
- Mark Latina, LLC — Reading
Michigan
- University of Michigan Kellogg Eye Center — Ann Arbor
- Kresge Eye Institute Wayne State University — Detroit
Ohio
- University Hospitals Eye Institute — Cleveland
- Cleveland Clinic Cole Eye Institute — Cleveland
Colorado
- Mile High Eye Institute — Sheridan
Florida
- Clear Vue Laser Eye Center — Lakeworth
Maryland
- Wilmer Eye Institute Johns Hopkins — Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 790 participants |
| Start Date | 2021-09-07 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04967989
The ClinicalTrials.gov registry entry for NCT04967989 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 790 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,082 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Glaucoma and Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions — of which Low Energy SLT is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04967989 reports 20 study locations spanning 11 distinct geographic areas — top geographies include California, Illinois, Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04967989 about?
NCT04967989 is a clinical study titled "Clarifying the Optimal Application of SLT Therapy Trial". The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeatin...
What is the current status of trial NCT04967989?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 790 participants. The study started on 2021-09-07. Estimated completion is 2027-08-31.
What conditions does trial NCT04967989 study?
This clinical trial studies the following conditions: Glaucoma and Ocular Hypertension. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04967989?
The interventions under investigation include: Low Energy SLT (PROCEDURE), Standard Energy SLT (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04967989?
This trial is sponsored by University of Pittsburgh, which has 1,082 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04967989 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.